Please ensure Javascript is enabled for purposes of website accessibility

Why Pfizer Stock Is Tumbling Today

By George Budwell - Mar 16, 2020 at 2:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Pfizer's deep ties to China are weighing on its shares today.

What happened

Pharmaceutical behemoth Pfizer (PFE 0.84%) is having another bad day today. The drugmaker's shares plunged by a jaw-dropping 9.5% right out of the gate Monday morning. While Pfizer's stock has regained some of this lost ground as today's trading session has unfolded, its shares are still down by 4.4% as of 1:11 p.m EDT Monday afternoon.

The pharma titan's stock has now lost almost 20% of its value since the start of 2020. On the bright side, Pfizer's shares have outperformed the Dow Jones Industrial Average so far this year. 

A businessman biting his fingernails.

Image source: Getty Images.

So what

Pfizer's stock seems to be plunging today mainly from the issues emanating out of China due to COVID-19. In brief, China reportedly experienced a sharp economic contraction during the first quarter of 2020, thanks to the government's implementation of extreme quarantine measures starting in January.

The tie-in to Pfizer is that the drugmaker has been generating a fair amount of drug sales in this key emerging market over the past several quarters, especially for its older legacy medicines. With China on lockdown over the past two months or so, Pfizer seems destined to report a noticeable decline in international pharmaceutical sales when the company announces first-quarter earnings later this year.  

Now what

Is Pfizer a bargain buy on this sharp pullback? Pfizer's dividend now stands at an eye-popping 4.65%, it has a strong balance sheet, a top-notch branded drug portfolio, and an elite clinical pipeline. The company also announced a five-point plan last Friday to engage in an industrywide collaborative effort to accelerate the development of both a vaccine and antiviral treatments indicated for COVID-19. So, if you can ride out this short-term volatility, Pfizer's stock is arguably worth buying right now.  

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
$52.02 (0.84%) $0.43
Dow Jones Industrial Average (Price Return) Stock Quote
Dow Jones Industrial Average (Price Return)
$31,497.31 (-0.01%) $-3.37

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.